Bolt Biotherapeutics(BOLT) - 2025 Q1 - Quarterly Results

Exhibit 99.1 Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update Recent Highlights and Anticipated Milestones • BDC-4182 Phase 1 dose-escalation study now open for enrollment • BDC-3042 Phase 1 dose-escalation data presented at AACR 2025 demonstrated a favorable safety profile, dose-dependent biological activity, and monotherapy anti-tumor activity • Bolt is running a partnering process to advance development of BDC-3042 • Cash balance of $58.0 million as of March ...